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Background: Emerging evidence suggests that small nucleolar RNAs (snoRNAs) are involved in tumorigenesis. The
roles of small nucleolar RNA 113–1 (SNORD113-1) on the development of hepatocellular carcinoma (HCC)
remain unknown.
Methods: The expression of SNORD113-1 was measured in 112 HCC tumor tissues using quantitative RT-PCR and
compared with expression levels from with paired non-tumor tissues. The effects of SNORD113-1 on HCC tumorigenesis
were investigated in HepG2 and Huh7 cells as well as a xenograft nude mouse model. CpG methylation within the
promoter region of the SNORD113-1 gene was identified using Sodium bisulfite sequencing. Cancer pathway reporter
investigate the mechanism by which SNORD113-1 suppressed tumorigenesis.
Results: SNORD113-1 expression was significantly downregulated in HCC tumors compared with adjacent non-tumor
tissues, and downregulation of SNORD113-1 in HCC tumors was significantly associated with worse survival of patients.
In addition, CpG methylation at the promoter region of the SNORD113-1 gene was higher in HCC tumors than adjacent
non-tumor tissues. Functionally, SNORD113-1 suppressed cancer cell growth in HepG2 and Huh7 cells and in a
xenograft nude mouse model. Furthermore, SNORD113-1 inactivated the phosphorylation of ERK1/2 and SMAD2/3 in
MAPK/ERK and TGF-β pathways.
Conclusions: SNORD113-1 functions as a tumor suppressor role in HCC and may be important as a potential
diagnostic and therapeutic target for HCC.Background
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer deaths [1]. The development and progression of
HCC occurs as a typical multistage disease, in which a
number of genes related to cellular processes such as cell
cycle control, cell growth, apoptosis and cell migration, are
deregulated [2]. Recently, an increasing number of studies
investigating the role of non-coding RNAs (ncRNAs) in the
pathology of HCC have been reported, including micro-
RNAs (miRNAs), long non-coding RNA (lncRNAs) and
small nucleolar RNAs (snoRNAs) [3-5].
SnoRNAs belong to a group of ncRNA molecules of
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unless otherwise stated.This group of ncRNAs is predominantly found in the
nucleolus and functions to guide RNAs for post-
transcriptional modification of ribosomal RNAs and
some spliceosomal RNAs [6]. Recent research has sug-
gested that malfunctioning snoRNAs may have roles in
the development and progression of human malignancy.
For instance, SNORA42 has been shown to act as an onco-
gene in lung tumorigenesis [7], SNORD33, SNORD66 and
SNORD76 are potential markers for non-small-cell lung
cancer [8], and HBII-239 snoRNA may have diagnostic and
prognostic significance for peripheral T-cell lymphoma [9].
Accumulating evidence suggests that snoRNAs may be ac-
tively involved in carcinogenesis and play diverse roles in
tumor biology.
In the present study, we demonstrated that small nu-
cleolar RNA 113-1(SNORD113-1) was significantly
downregulated in HCC tissues as compared with adja-
cent non-tumor tissues, and this downregulation of
SNORD113-1 was associated with decreased survival ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1 was regulated by CpG island methylation of the puta-
tive promoter region. Functional analyses indicated
SNORD113-1 inhibited both cell growth and tumori-
genicity of HCC cells, possible through effects on
MAPK/ERK and TGF-β pathways.
Results
Differential expression of mRNAs in HCC
To identify novel differential gene expression in HCC
tissues, Human Transcriptome Arrays were performed
on 3 pairs of HCC tumors and adjacent non-tumor tis-
sues (Table 1A). In total, 3233 differentially expressed
mRNAs were identified (fold change ≤ −0.5 or ≥ +2, P-
value ≤ 0.05), including 2065 upregulated and 1168
downregulated mRNAs. 29 upregulated mRNAs and 35
downregulated mRNAs showed greater than 10-fold
changes compared to non-tumor tissues (Table 2). The
four most upregulated genes were pepsinogen C (PGC),
alpha fetoprotein (AFP), aldoketo reductase family 1
member B10 (AKR1B10) and glypican 3 (GPC3), which
showed greater than 30-fold higher expression in HCC
tumors than adjacent non-tumor tissues. In contrast,
the five genes that demonstrated the most significant
downregulation were tyrosine aminotransferase (TAT),
Jun dimerization protein 2 (JDP2), hydroxysteroid (17-
beta) dehydrogenase 13 (HSD17B13), cytochrome P450
family 2 subfamily B polypeptide 6 (CYP2B6), andTable 1 The data of patients
A
Patients Age Tumor size Tumor grade TNM stage
P1 58 12 G3 III
P2 63 10.5 G3 III















*Diameter of the biggest nodule.
**TNM: tumor-node-metastasis.phosphoenolpyruvate carboxykinase 1 (PCK1), which
showed greater than 30-fold lower expression in HCC tu-
mors than adjacent non-tumor tissues. Interestingly, four
C/D box small nucleolar RNAs, including SNORD113-1,
SNORD114-1, SNORD113-6 and SNORD114-17, were
significantly downregulated in tumor tissues compared to
normal liver tissue.
Downregulation of SNORD113-1 was associated with
aggressive biological behavior of HCCs
To validate the array data, qRT-PCR was performed on
RNA extracted from 112 pairs of HCC and non-tumor
tissues. All of the four snoRNAs identified in our micro-
array analyses demonstrated downregulation in greater
than 50% HCC tumors (data not shown), of which
SNORD113-1 was downregulated in 77.6% (87/112) of
HCC samples (Figure 1A).
Furthermore, patients whose primary tumors did not
demonstrate significant downregulation of SNORD113-1
had a trend of increased relapse-free survival compared
with those patients whose primary tumors demonstrated
SNORD113-1 downregulation (Figure 1B), independent of
the tumor stage or size. The mean relapse-free survival in
patients with low SNORD113-1 expression (n = 87) was
68.4 months, whereas the mean relapse-free survival in
those with high SNORD113-1 expression (n = 25) was
99.8 months. No statistically significant correlations were
observed between SNORD113-1 expression and other
clinically pathological features (age, sex, HBV viral load,
HBsAg or HBeAg) (data not shown).
CpG hypermethylation downregulated SNORD113-1
expression in HCC
The methylation inhibitor, 5-Ad, was used to demethyl-
ate genomic DNA. As shown in Figure 2A, SNORD113-
1 expression levels were increased 2.06-fold in HepG2
cells following treatment with 5 μmol/L 5-Ad for 48 h
compared with vehicle-treated cells.
The Dlk1-Dio3 genomic region contains the paternally
expressed genes Dlk1, Rtl1, and Dio3, and the maternally
expressed genes MEG3 and MEG8 (Figure 2B, upper
panel) [10]. This region also hosts 54 miRNAs and many
snoRNAs, in particular 1, 9, and 31 paralogous copies of
SNORD112, SNORD113 and SNORD114, respectively
(Figure 2B, upper panel) [10]. To explore the relationship
between promoter methylation and SNORD113-1 gene
downregulation, we utilized CpG island prediction software
to analyze the promoter region of SNORD113-1. As shown
in Figure 2B and Additional file 1: Table S2, fragment 1 (F1,
82370922 ~ 82371234 in chromosome 14, NC_000014.8)
was rich in CpG dinucleotides and predicted as a putative
promoter region by three software programs.
To test whether fragments 1–4 were functionally im-
portant, promoter assays were performed using reporter
Table 2 Deregulated mRNAs in Hepatitis B virus-associated HCC
Symbol Description Fold change p-value
Up-regulated mRNAs
PGC progastricsin (pepsinogen C) 47.64004927 0.0023
AFP alpha-fetoprotein 44.39471392 0.0034
AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 34.90323855 0.0031
GPC3 glypican 3 33.3617948 0.0025
REG3A regenerating islet-derived 3 alpha 29.11429945 0.0016
SPP1 secreted phosphoprotein 1 (osteopontin, early T-lymphocyte activation 1) 23.96828868 0.0031
SQLE squalene epoxidase 23.32641995 0.0035
FADS2 fatty acid desaturase 2 20.89067206 0.0015
CDR1 cerebellar degeneration-related protein 1, 34kDa 18.83885007 0.0034
ACSL4 acyl-CoA synthetase long-chain family member 4 17.80369764 0.0051
Q9BT26_HUMAN MGC10981 protein. [Source:Uniprot/SPTREMBL; Acc:Q9BT26] 16.69515983 0.0016
MEP1A meprin A, alpha (PABA peptide hydrolase) 16.42375379 0.0023
TOP2A topoisomerase (DNA) II alpha 170kDa 16.41288559 0.0031
MKI67 antigen identified by monoclonal antibody Ki-67 15.96034575 0.0035
NQO1 NAD(P)H dehydrogenase, quinone 1 15.93951691 0.0042
CENPF centromere protein F, 350/400ka (mitosin) 14.37592617 0.0028
ANLN anillin, actin binding protein 14.34102265 0.0018
Q6ZN80_HUMAN CDNA FLJ16351 fis, clone TESTI2039060, moderately similar to
Maltase- glucoamylase, intestinal. [Source: Uniprot/SPTREMBL; Acc:Q6ZN80]
14.12849608 0.0037
ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 13.47005653 0.0031
PROM1 prominin 1 12.79763216 0.0029
SPINK1 serine peptidase inhibitor, Kazal type 1 12.7974104 0.0051
Q6ZUK9_HUMAN CDNA FLJ43606 fis, clone SPLEN2009548 (Hypothetical LOC613266).
[Source: Uniprot/SPTREMBL; Acc:Q6ZUK9]
12.61622159 0.0037
SULT1C2 sulfotransferase family, cytosolic, 1C, member 2 12.22079301 0.0029
LYZ lysozyme (renal amyloidosis) 11.95607544 0.0016
LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 11.46664156 0.0028
HIST2H4A histone cluster 2, H4a 10.97942046 0.0034
FMO1 flavin containing monooxygenase 1 10.69015599 0.0009
NUSAP1 nucleolar and spindle associated protein 1 10.56415889 0.0038
BPIL1 bactericidal/permeability-increasing protein-like 1 10.11522846 0.0051
Down-regulated miRNAs
TAT tyrosine aminotransferase 0.016479668 0.0037
JDP2 Jun dimerization protein 2 0.017312537 0.0027
HSD17B13 hydroxysteroid (17-beta) dehydrogenase 13 0.018812312 0.0018
CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6 0.025612431 0.0031
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) 0.029105346 0.0023
NR_003229.1 small nucleolar RNA, C/D box 113–1 (SNORD113-1) on
chromosome 14 [Source: RefSeq_dna; Acc:NR_003229]
0.040807072 0.0028
GLYAT glycine-N-acyltransferase 0.041146571 0.0034
NR_001278.1 cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1
(CYP2B7P1) on chromosome 19 [Source: RefSeq_dna; Acc:NR_001278]
0.046105574 0.0037
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 0.047541954 0.0046
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 0.048856354 0.0008
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SDS serine dehydratase 0.049689196 0.0035
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 0.052959819 0.0019
MFSD2 major facilitator superfamily domain containing 2 0.053182596 0.0016
GYS2 glycogen synthase 2 (liver) 0.054336295 0.0031
SLC22A1 solute carrier family 22 (organic cation transporter), member 1 0.059035231 0.0029
ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide 0.061977699 0.0046
NR_003193.1 small nucleolar RNA, C/D box 114–1 (SNORD114-1) on
chromosome 14 [Source: RefSeq_dna; Acc: NR_003193]
0.064302828 0.0027
BCO2 beta-carotene oxygenase 2 0.068982298 0.0031
PZP pregnancy-zone protein 0.068984067 0.0061
HPD 4-hydroxyphenylpyruvate dioxygenase 0.069601683 0.0043
MT1G metallothionein 1G 0.071319826 0.0037
CRHBP corticotropin releasing hormone binding protein 0.073777924 0.0031
MT1M metallothionein 1M 0.076630206 0.0026
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 0.078040509 0.0052
COLEC10 collectin sub-family member 10 (C-type lectin) 0.085870417 0.0048
NR_003234.1 small nucleolar RNA, C/D box 113–6 (SNORD113-6) on
chromosome 14 [Source: RefSeq_dna; Acc: NR_003234]
0.086148113 0.0037
SLC10A1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1 0.086419698 0.0034
CYP8B1 cytochrome P450, family 8, subfamily B, polypeptide 1 0.088848979 0.0016
CNDP1 carnosine dipeptidase 1 (metallopeptidase M20 family) 0.089111411 0.0018
FOSB FBJ murine osteosarcoma viral oncogene homolog B 0.092529294 0.0027
MT1P2 metallothionein 1 pseudogene 2 0.092597882 0.0034
C7 complement component 7 0.093307121 0.0036
NR_003210.1 small nucleolar RNA, C/D box 114–17 (SNORD114-17) on
chromosome 14 [Source: RefSeq_dna; Acc: NR_003210]
0.094172719 0.0043
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 0.096675826 0.0019
XDH xanthine dehydrogenase 0.099523084 0.0022
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In transient transfection experiments, F1 displayed
143.5-fold higher promoter activity than those of the
pGL3-basic lacking eukaryotic promoter and enhancer
control plasmids (Figure 2C), respectively. These data
clearly indicated that F1 contained functionally import-
ant sequences for gene expression.
To examine the methylation pattern, F1, containing a
total of 27 CpG dinucleotides, was amplified from gen-
omic DNA isolated from HCC and non-tumor tissues
treated with either sodium bisulfite or vehicle. Figure 2D
shows a representative methylation pattern of the 27
CpGs putative promoter region. In non-tumor tissues,
the majority of CpGs were unmethylated, whereas in
the tumor tissues, most of the CpGs were methylated
(Figure 2D, left panel). The methylation status of each
CpG was quantified using the percentage of methylated
CpGs among all PCR products analyzed. 44.4% (12/27)
CpGs were hypermethylated in tumors compared withnormal pituitaries (Figure 2D, right panel). Thus, methy-
lation in the putative promoter region of SNORD113-1
gene was higher in HCC tumor tissues than in those
from adjacent non-tumor tissues.SNORD113-1 suppressed HCC tumorigenesis in vitro and
in vivo
The significant downregulation of SNORD113-1 expres-
sion in HCC tissues suggested possible biological signifi-
cance in tumorigenesis. First, we evaluated the effects of
SNORD113-1 on cell growth in HepG2 and Huh7 cells
transfected with either p3.1-SNORD113-1 or
SNORD113-1 siRNA. Measured using qRT-PCR, the ex-
pression of SNORD113-1 was 57.4-fold (HepG2) and
63.5-fold (Huh7) increased in cells transfected with
p3.1-SNORD113-1, but 32.2-fold (HepG2) and 23.4-fold
(Huh7) deceased in cells transfected with 20nM
SNORD113-1 siRNA (Figure 3A). Cells treated with
Figure 1 SNORD113-1 was downregulated in HCC tumor tissues. A. Downregulated expression of SNORD113-1 in HCC tumor tissues
compared with adjacent non-tumor tissues (n = 112,*p < 0.05, **p < 0.01). B. Probability of cancer-specific survival determined using levels of
SNORD113-1 expression in HCCs.
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differences in SNORD113-1 expression.
Three days following transfection, the viability of cells
transfected with p3.1-SNORD113-1 decreased 28.7 ~
30.2% compared with cells transfected with empty vector
or non-transfected cells. However, the viability of cells
transfected with SNORD113-1 siRNA increased by 31.5 ~
32.3% (Figure 3B). These results indicate that SNORD113-
1 suppressed HCC cell growth. To validate the suppres-
sion of SNORD113-1 on cell growth, we performed colony
formation assays in HepG2 and Huh7 transfected with
p3.1-SNORD113-1 or transfected with SNORD113-1
siRNA. As shown in Figure 3C, HepG2 and Huh7 cells
transfected with p3.1-SNORD113-1 formed much fewer
and smaller colonies (135 or 351 colonies) compared with
empty vector transfected (491 or 892 colonies) and non-
tranfected cells (483 or 857 colonies). In contrast, cells
transfected with SNORD113-1 siRNA formed more nu-
merous and larger colonies (618 or 1043 colonies). To fur-
ther confirm the above findings, a xenograft mouse model
was used. As shown in Figure 3D, tumors generated by in-
jection with p3.1-SNORD113-1 transfected HepG2 cells
were significant smaller after 5 weeks, compared with the
scramble siRNA transfected or non-transfected HepG2
cell groups. However, tumors generated from SNORD113-
1 siRNA transfected HepG2 cells were significant larger 4
and 5 weeks after injection. These results indicate thatintroduction of SNORD113-1 significantly suppressed
tumorigenesis in a xenograft nude mouse model.
Cell cycle analysis showed that the percentages of p3.1-
SNORD113-1 transfected HepG2 cells in the S phase were
8.85% more than that of empty vector transfected or non-
transfected cells, with a parallel 7.72% decrease of cells in
the G2-M phase (Figure 3E). In SNORD113-1 siRNA
transfected cells, the percentage of cells in the S phase was
6.93% less than that of scramble siRNA transfected or
non-transfected cells, which corresponded with a 6.99%
increase in cells in the G2-M phase (Figure 3E). There
were no significant differences in the total duration of the
cell-cycle between p3.1-SNORD113-1 or SNORD113-1
siRNA transfected and non-transfected cells (data not
shown). Similar results were observed in Huh7 cells. In
addition, in both p3.1-SNORD113-1 and SNORD113-1
siRNA transfected cells, the percentages of apoptotic cells
were similar to that of the control group (Figure 3F). To-
gether, these results suggest that SNORD113-1 could sup-
press HCC cell proliferation by inducing cell cycle arrest
rather than apoptosis.
To further examine the effects of SNORD113-1 on
HCC tumorigenesis, the migration of HCC cells in trans-
well culture chambers was investigated. As shown in
Figure 3G, the migration rates of p3.1-SNORD113-1 or
SNORD113-1 siRNA transfected HepG2 cells were simi-
lar. In addition, Matrigel invasion assays were carried out
Figure 2 Hypermethylation of CpGs mediated decreased SNORD113-1 expression. A. Demethylation following treatment with 5-aza-2′-
deoxycytidine induced SNORD113-1 upregulation. Left panel: a representative result; Right panel: the results from three experiments. B. Upper
panel: a schematic of the Dlk1-Dio3 region in 14q32 [10]; Lower panel: the CpG island enriched sites in the upstream region of SNORD113-1 were
analyzed using CpG island searcher, CoreBoost_HM and MethPrimer. C. Strong promoter activity of fragment 1 (F1) was demonstrated using
luciferase assays. D. Bisulfite sequencing of the putative promoter region. Left panel, each line represents one PCR product, and five PCR products
are shown for each sample. ●, methylated CpGs; ○, unmethylated CpGs. Right panel, the methylation status of each CpG in this region was
quantified using the percentage of methylated CpGs among all PCR products. *p < 0.05, **p < 0.01.
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behavior of HCC cells, however, no significant differences
were observed (Figure 3G). These results suggested that
SNORD113-1 had no effect on the migration and invasion
of HCC cells.
MAPK/ERK and TGF-β pathway were involved in
SNORD113-1 effects
In order to identify SNORD113-1 target genes, the global
mRNA expression in HepG2 cells transfected with either
p3.1-SNORD113-1 or SNORD113-1 siRNA was analyzed
with Human Gene Expression Arrays. Unexpectedly,
SNORD113-1 had little effect on global gene expression;
only a very small number of genes that demonstratedsignificant changes in expression levels (fold change ≤ −0.5
or ≥ +2, P-value ≤ 0.05) after SNORD113-1 overexpression
or knockdown were identified (data not shown). These re-
sults suggest that SNORD113-1 might exert inhibitory ef-
fects through a novel indirect mechanism.
To investigate the mechanism of SNORD113-1
suppression of tumor growth in HCCs, 10 major cancer-
related pathways were analyzed in p3.1-SNORD113-1 or
SNORD113-1 siRNA transfected HepG2 cells using a
dual-luciferase reporter system (Promega). Figure 4A
shows the relative reporter expression in HepG2 cells
transfected with p3.1-SNORD113-1 normalized to that of
cells transfected with pcDNA3.1. The most affected path-
ways were transforming growth factor-β (TGF-β) and
Figure 3 SNORD113-1 inhibited colony formation in culture and tumorigenesis. A. The expression of SNORD113-1 in HepG2 (□) and Huh7
(■) cells with or without infection of p3.1-SNORD113-1, SNORD113-1 siRNA or NC duplex. B. The effects of SNORD113-1 on cell viability in HepG2
cells. C. The effects of SNORD113-1 on colony formation in HepG2 cells. Left panel: the representative result of a colony formation assay; Right
panel: the mean value from all three independent experiments determining colony formation. D. The effects of SNORD113-1 on xenograft tumor
growth in nude mice. E. The effects of SNORD113-1 on cell cycle in HepG2 cells. F. The effects of SNORD113-1 on apoptosis in HepG2 cells. Upper
panel: the results of apoptosis analysis measured with flow cytometry; Lower panel: the results of apoptosis analysis determined using caspase3/7 activity
measurements. G. The effects of SNORD113-1 on cell migration and invasion in HCC cell lines. Upper panel: the representative result of cell migration and
invasion; Lower panel: the mean value from at least three independent experiments of cell migration and invasion. *p < 0.05, **p < 0.01.
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signal-regulated kinase (ERK). Figure 4B shows the relative
reporter expression in HepG2 cells transfected with
SNORD113-1 siRNA normalized to that of cells trans-
fected with NC siRNA. The most affected pathways were
also TGF-β and MAPK/ERK. The downregulation of the
MAPK/ERK and TGF-β pathways in cells overexpressing
SNORD113-1 were consistent with the upregulation of
the MAPK/ERK and TGF-β pathways in SNORD113-1
knockdown cells.
To verify these findings, the key molecules in the MAPK/
ERK and TGF-β pathways were detected by immunoblot-
ting. SNORD113-1 overexpression significantly decreased
phosphorylation of MEK and ERK1/2 (Figure 4C), whereas
total ERK and total MEK expression were not signifi-
cantly altered (Figure 4C). Similarly, upon examination
of the TGF-β pathway, phosphorylation of SMAD2/3was decreased by SNORD113-1 overexpression (Figure 4D).
These results were reversed under conditions of
SNORD113-1 knockdown. These results indicate that
both the MAPK/ERK and TGF-β pathways may be in-
volved in SNORD113-1 suppression of tumorigenesis.
Discussion
Among the upregulated genes, PGC, AFP, AKR1B10 and
GPC3 showed more than 30-fold increased expression
in the HCC tumor group. AFP is the only serum bio-
marker that has widely been used in the diagnosis of
HCC [11]; GPC3 is also a potential reliable biomarker
and therapeutic target in HCC [12]; PGC is overex-
pressed in HCC [13]; AKR1B10 is a valuable novel bio-
marker candidate for staging of HCC [14]. In addition,
other genes, including secreted phosphoprotein 1 (SPP1,
osteopontin), fatty acid desaturase 2 (FADS2) and serine
Figure 4 MAPK/ERK and TGF-β pathway were involved in SNORD113-1 effect. A, B. The relative reporter expression in HepG2 transfected
with p3.1-SNORD113-1 (A) or SNORD113-1 siRNA (B) determined using Cignal Finder 10 Cancer Pathway Reporter Assays. HepG2 cells transfected
with p3.1-SNORD113-1 or SNORD113-1 siRNA were seeded onto 96-well plates containing luciferase reporters to 10 common cancer pathways
along with FuGene HD transfection reagent. Luciferase activity of the cells was measured using the dual luciferase assay system. Relative firefly
luciferase activity was calculated and normalized to the constitutively expressed Renilla luciferase. C, D. The effect of SNORD113-1 on MAPK/ERK
pathway (C) or TGF-β pathway (D). The expression and phosphorylation of key molecules of the pathways were detected using immunoblotting.
GAPDH was used as an internal control.
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reported to be associated with HCC progression [15-17].
Among the downregulated genes, TAT, JDP2, HSD17B13,
CYP2B6 and PCK1 showed more than 30-fold decreased
expression in HCC tumors, and all of these genes have
been reported to be associated with HCC progression pre-
viously, except HSD17B13 [18-21]. The identification of
these well-known HCC biomarkers suggested that the re-
sults of the array were reliable. In order to identify novel
molecular and potential biomarkers for HCC tumorigen-
esis, downregulated snoRNAs were chosen for this study.
With regard to a link between snoRNA and tumorigen-
esis, Dong et al. reported that U50 undergoes frequentgenomic heterozygous deletions and transcriptional down-
regulation, and U50 overexpression reduces the colony-
forming ability in both prostate and breast cancer cells
[22,23]. Horsthemke et al. reported that a diverse number
of snoRNAs are differentially expressed in non-small cell
lung cancer with respect to the corresponding matched tis-
sue [24]. More recently, Mei et al. reported that SNORA42
expression in non-small cell lung cancer cells increased col-
ony formation in culture and tumorigenesis [7]. Together,
these findings suggest a possible role of snoRNAs in onco-
genesis. In the present study, SNORD113-1 exhibited a
strong ability to inhibit cell growth and proliferation in hu-
man HCC cells. In addition, the results from a xenograft
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SNORD113-1 can regulate HCC tumor cell growth and
that the loss of SNORD113-1 gene function may be dir-
ectly associated with tumor development. The activity of
SNORD113-1 caused growth suppression. In addition,
SNORD113-1 was expressed in normal liver tissues but
absent in paired HCC tissues, suggesting that it may play
an important role in the maintenance of normal cell
growth. These exciting findings suggest that SNORD113-1
may play a role as a tumor suppressor gene. However, the
sequence of SNORD113-1 was cloned into a plasmid and
overexpressed in cells, and the correct processing of the
sequence into the mature SNORD113-1 requires further
confirmation.
The SNORD113-1 gene is located at chromosome
14q32 within an intron of the small nucleolar RNA host
gene 23 (SNHG23, Gene ID: 100507242) together with
many miRNAs and other C/D snoRNAs. Interestingly,
genomic alterations in the 14q32 locus have been ob-
served in HCC and colorectal carcinomas [25,26]. Loss of
heterozygosity (LOH) is considered to be an indicator of
the presence of a tumor suppressor gene (TSG), whereas
inactivation at the locus contributes to the development
and/or progression of tumors [27]. In the present study,
LOH of the SNORD113-1 gene was found in only 11.1%
(4/36) HCC tumor tissues (data not shown), which was
less than the 43.6% LOH reported previously [25,26].
Zhang et al. suggested that allelic loss at the MEG3 locus
was more prevalent in higher grade tumors [28], and this
discrepancy in our results compared to those previously
reported might be due to differences in the grades in the
HCC tumors examined in each study.
In most cases, the levels of the intron encoded snoRNA
genes seem to be determined by the transcription of their
host genes [29]; thus the transcription of those snoRNA
might be synchronized to their host genes. The intergenic
snoRNA genes are independently transcribed from their
own promoters by RNA polymerase II (Pol II) [30]. Gener-
ally, the 5′UTR lengths of protein-coding genes are within
50 bps to 100 bps. In contrast, the distances between
intergenic miRNA transcription start sites (TSS) and their
precursor’s TSS significantly fluctuate from less than
100 bps to 50 kb [31,32]. Using CpG island prediction
software, we did not identify any CpG islands within the
3000 bp upstream region of the SNORD113-1 gene. The
region from 2000 bp upstream of MEG8 to the 0 bp up-
stream region of SNORD113-1 was analyzed with the
CpG island prediction software. Sequence information
showed that a region (fragment 1) located approximately
12 kb upstream of SNORD113-1 gene was rich in CpG di-
nucleotides, suggesting that this region was a putative pro-
moter region of SNORD113-1. The results of sodium
bisulfite treatment demonstrated that the SNORD113-1
fragment 1 in HCC tumors contained significantly highernumbers of methylated CpGs than those in non-tumor
tissues. Studies have also shown that epigenetic silencing
of snoRNAs with tumor suppressor activities by CpG is-
land hypermethylation is a common feature of human
cancers. Ferreira et al. reported that 43.5% (20/46) of
snoRNAs were fully methylated in the colorectal cancer
cell line hcT-116, which suggests that CpG island hyper-
methylation is associated with the transcriptional silencing
of their respective snoRNAs [33]. The results of DNA
methylation microarray platform demonstrated that the
observed hypermethylation of snoRNAs was a common
feature of various tumor types [33]. MEG3 has been
shown to be methylated in human renal cell carcinoma
tissues and cell lines, as well as in pheochromocytomas
and human pituitary tumors [34-36], and promoter hyper-
methylation downregulated MEG3 expression and pro-
motes oncogenesis [36]. Thus, the fragment 1 was the
most likely promoter region for SNORD113-1.
Most noncoding RNA promoters are computationally
predicted without experimental validation. Until now, only
a few of the promoters predicted using chromatin signa-
tures have been confirmed by promoter reporter assays
[37,38]. In the present study, fragment 1 clearly demon-
strated strong promoter activity in activation of reporter
gene expression. In addition, the expression of SNORD113-
1 in HepG2 cells induced by a demethylation reagent indi-
cates that methylation is related to SNORD113-1 gene
transcription. Taken together, these results suggest that
hypermethylation of fragment 1 is an important mechanism
associated with the loss of SNORD113-1 expression in hu-
man HCC tumors. However, it has been shown that non-
CpG promoters demonstrated the highest levels of predic-
tion inaccuracy [39], and it is currently unclear whether
there are non-CpG promoters within the 8000 bp region
from fragment 1 to fragment.
Two distinct, differentially methylated regions (DMR)
are present in the Dlk1-Dio3 region and have separate
functional properties: a primary, germline-derived Dlk1-
MEG3 intergenic DMR (IG-DMR) and a secondary, post-
fertilization-derived MEG3-DMR [10]. Seitz H, et al.
concluded that the miRNA genes tested in Dlk1-Dio3 re-
gion exhibited a tissue-specific expression pattern, and
they were only expressed from the maternally inherited al-
lele with imprinted expression controlled by a differen-
tially methylated region (DMR) located ∼ 200 kb away
[40]. Manodoro F, et al. also reported the methylation of
DMR was associated with acute promyelocytic leukemia
[41]. However, our findings are different from these previ-
ous studies. In the present study, we also examined the
methylation status of DMR and the expression of genes,
snoRNAs and miRNAs in the Dlk1-Dio3 region of our
HCC tumors compared with adjacent non-tumor tissues.
No significant differences in methylation within the IG-
DMR were found between HCC tumors and adjacent
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pressions of Dlk1, SNORD113-3, miR-370 and miR-485,
and others were significantly downregulated, but the ex-
pressions of Dio3, miR-127, miR-136, miR-154 and miR-
544, and others demonstrated no significant changes
(Additional file 2: Table S3). These results revealed that
the expression of SNORD113 and SNORD114 clusters
and miRNAs which are located behind the putative pro-
moter region (F1 in this study) have similar expression
patterns, suggesting that they might share the same pro-
moter. However, differential expression patterns of
some miRNAs in the Dlk1-Dio3 region suggest that
there are additional regulatory mechanisms, such as
post-transcriptional modifications.
The sequences of snoRNAs are responsible for target-
ing the assembled snoRNPs to a specific target [42].
SnoRNAs and snoRNPs are likely to contribute to
tumorigenesis through effects on ribosomes and protein
translation, given that translation is often perturbed in
cancer cells. However, snoRNAs might also be involved
in the regulation of gene expression by giving rise to
other regulatory RNA species, such as miRNAs [43]. To
further examine whether SNORD113-1 could affect gene
expression and explore its possible functions, HepG2
cells transfected with p3.1-SNORD113-1 or SNORD113-
1 siRNA were analyzed by mRNA transcript arrays.
SNORD113-1 showed little effects on global gene ex-
pression in the mRNA transcript arrays, which is con-
sistent with previous reports examining other small
nucleolar RNAs [44]. Furthermore, MAPK/ERK and
TGF-β pathways were found altered in response to changes
in SNORD113-1 expression levels. Immunoblotting ana-
lyses showed that phosphorylated MEK and ERK compared
to total ERK, as well as phosphorylated SMAD2/3 com-
pared to total SMAD2/3 and SMAD4, were increased both
in SNORD113-1 siRNA transfected HepG2 cells and in
HCC tumor tissues. SNORD113-1 had few effects on
mRNA levels but significant effects on protein phosphoryl-
ation levels suggesting that snoRNAs may act through in-
direct mechanisms on these targets. The MAPK/ERK
signaling pathway is involved in diverse cellular processes
such as cell survival, differentiation and proliferation [45],
and overexpression of members of this pathway was found
to be correlated to HCC [46]. Similarly, the TGF-β pathway
also regulates cell proliferation, differentiation and ad-
hesion [47]. These two pathways have been reported to
play significant roles in HCC tumorigenesis [48]. These
results suggest MAPK/ERK and TGF-β pathways are
most likely involved in SNORD113-1 suppression of
HCC tumorigenesis.
In the present study, downregulation of SNORD113-1
was frequently observed in HCC tumors but rarely
present in non-tumor tissues. Importantly, SNORD113-
1 expression was correlated with disease-free survival ofHCC patients. These results obtained from clinical spec-
imens provide evidence to support the hypothesis that
decreased expression of SNORD113-1 contributes to
HCC development and progression. In addition, overex-
pression of SNORD113-1 could inhibit cell viability and
proliferation of cancer cells, and thus have an important
role in the development of HCC. Therefore, SNORD113-1
may present not only a useful molecular marker for select-
ing patients with poor prognosis to receive more personal-
ized therapy, but also a potential therapeutic target for
HCC. Nevertheless, validating its prognostic value in a
large population and developing novel strategies for im-
proving treatment efficiencies of HCC are needed.
Conclusions
In conclusion, the results from these studies demonstrated
that SNORD113-1 suppresses HCC tumorigenesis in
MAPK/ERK and TGF-β pathway-dependent mechanisms.
Methods
Cell lines and tissue specimens
Human embryonic kidney cell line Hek293T and human
HCC cell lines HepG2 and Huh7 were cultured in DMEM
medium supplemented with 10% FBS (Life Technology,
Carlsbad, CA) at 37°C in a humidified atmosphere con-
taining 5% CO2.
112 pairs of human hepatitis B virus (HBV) associated
HCC and adjacent non-tumor tissues were obtained
from surgical specimens immediately after resection
from patients undergoing primary surgical treatment of
HCC in the Eastern Hepatobiliary Surgery Hospital,
Shanghai, China. The samples were frozen in liquid nitro-
gen and stored at −80°C for use in experiments. Among
these samples, three pairs were used for mRNA array ana-
lyses (Table 1A) and all of them were used for quantitative
real time PCR (qRT-PCR) analyses (Table 1B). Clinical
and pathological information was extracted from the pa-
tients’ medical charts and pathology reports (Table 1).
Written consent for tissue donation (for research pur-
poses) was obtained from the patients prior to tissue col-
lection and the protocol was approved by the Institutional
Review Board of Eastern Hepatobiliary Surgery Hospital
and Second Military Medical University.
Total RNA extraction and gene expression profiling
Total RNA was isolated using TRI Reagent combined
with the RNeasy Tissue kit protocol (Qiagen, Valencia,
CA) according to the manufacturer’s recommendations.
The RNA concentrations and the A260 nm/A280 nm ra-
tios were assessed with a multi-plate reader (Synergy 2;
BioTek, Winooski, VT). The 28S/18S ratio and the RNA
integrity number were assessed with a Bioanalyzer 2100
(Agilent Technologies, Wilmington, DE). An A260 nm/
A280 nm ratio of 1.9, a 28S/18S ratio of 1.8, and an
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for inclusion in expression analysis.
To identify differentially expressed genes in HCC tumor
tissues, The Glue Grant Human Transcriptome Arrays
(Affymetrix, Santa Clara, CA) were performed on 3 pairs
of HCC and adjacent non-tumor tissues (Table 1A) ac-
cording to the manufacturer’s protocol by Gminix Corp.
(Shanghai, China). For SNORD113-1 related gene identifi-
cation, the global mRNA expression of HepG2 cells trans-
fected with p3.1-SNORD113-1, SNORD113-1 siRNA,
empty vector, scramble siRNA or untransfected cells were
analyzed with the PrimeView™ Human Gene Expression
Array (Affymetrix) according to the manufacturer’s proto-
col by Shanghai Biotechnology Corp. (Shanghai, China).
A total of 750 ng of labeled complementary RNAs were
hybridized to arrays and then imaged using Affymetrix
Fluidics Station FS450 and scanned with GeneChip Scan-
ner 3000 7G according to manufacturer’s instructions.
Raw signals of the arrays were processed using Affymetrix
Power Tools. Data quality was assessed based on the posi-
tive and negative control probes on each array as well as
by inspection of the distributions of probe intensities. Data
was normalized using the quantile normalization method.
A moderated t-test implemented in the limma library of
bioconductor was applied to test differential expression,
and a false discovery rate (FDR) adjustment of the p-value
was performed to correct for multiple testing. Probes were
considered significantly different if the adjusted p-value
was less than 0.05 and the fold change difference between
groups was at least 2.
Quantitative real time PCR
Quantitative real time PCR (qRT-PCR) analysis of
SNORD113-1 expression was carried out according to
the manufacturer’s protocol. Briefly, total RNA was ex-
tracted using TRIzol Reagent (Invitrogen) from HCC tis-
sues or cell lines and was used to synthesize cDNAs
with SNORD113-1 specific reverse primers. The reac-
tions were incubated for 30 min at 16°C, 30 min at 42°C,
5 min at 85°C, and then held at 4°C. The cDNA product
was used for qRT-PCR analysis directly with primers for
SNORD113-1 (Additional file 3: Table S1). Reactions
were incubated at 95°C for 5 min, followed by 40 cycles
at 95°C for 15 sec and 60°C for 1 min. PCR reactions
were run on a StepOne Plus real time PCR machine
(Applied Biosystems) and the data were analyzed using
SDS v2.3 software. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and U6 were used as reference
controls for normalization. For 5-aza-2′-deoxycytidine
treatment, HepG2 cells were seeded into 60 × 15-mm
tissue culture dishes and cultured in DMEM containing
5 μmol/L 5-aza-2′-deoxycytidine (5-Ad, Sigma-Aldrich,
St. Louis, MO) for 48 hours. Cells cultured in the ab-
sence of 5-Ad were used as a negative control.SNORD113-1 mRNA expression was determined using
qRT-PCR as described above. The PCR products were
also separated by 1.5% agarose gel electrophoresis, visu-
alized and analyzed by the Tanon UV-2000 (Tanon,
Shanghai, China).
Plasmid constructions, transfection and luciferase
reporter assay
The synthesized SNORD113-1 (AAAGTGAGTGATGA
ATAGTTCTGTGGCATA TGAATCATTAATTTTGAT
TAAACCCTAAACTCTGAAGTCC, Genebank: NR_0
03229.1, by Genery, Shanghai, China) was cloned into
pcDNA3.1 vector (Life Technology). The constructs
were confirmed by sequencing and termed as p3.1-
SNORD113-1. The expression of SNORD113-1 was
confirmed by qRT-PCR.
Transfection was carried out using FuGene HD trans-
fection reagent (Roche, Indianapolis, IN) following the
manufacturer’s protocol. In brief, 2 × 104 HepG2 and
Hek293T cells in 24-well plates were transfected with
the indicated plasmids, specific or scramble siRNA
(GenePharma, Shanghai, China), and collected 48 hours
after transfection for assays.
The fragments of the putative promoter region (F1,
Figure 2B) and 3000 bp upstream of the gene of
SNORD113-1 (which was divided to three fragments of
1000 bp) (F2, F3 and F4, Figure 2B) were amplified with
primers (Additional file 3: Table S1) and cloned into a
promoter-less luciferase reporter vector pGL3-Basic (Pro-
mega Corp. Madison, WI), termed as pGL3-F1, pGL3-F2,
pGL3-F3 and pGL3-F4. HEK293T cells were seeded on a
24-well plate in triplicate and transfected with pGL3-F1,
pGL3-F2, pGL3-F3, pGL3-F4 or empty vector pGL3 using
FuGene HD transfection reagent. The pRL-TK was also
transfected as a control for normalization. Cells were col-
lected 48 hours after transfection, and luciferase activity
was measured using a dual-luciferase reporter assay kit
(Promega Corp.) and measured using a multi-plate reader
(Synergy 2, BioTek).
Sodium bisulfite sequencing




omic DNA from HCC tumor tissues or adjacent non-
tumor tissues was extracted using DNeasy Tissue Kit
(QIAGEN, Valencia, CA). One microgram of genomic
DNA was treated with sodium bisulfite using the
CpGenome DNA Modification Kit (Serologicals Corp.,
Norcross, GA) according to the manufacturer’s proto-
col. Hotstart PCRs were performed with the primers
(Additional file 3: Table S1, bisulfit-1 and bisulfit-2)
under the following conditions: 95°C for 15 min, 94°C
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40 cycles, and 72°C for 10 min. PCR products were
subcloned, and five constructs representing each re-
gion from each sample were randomly selected for se-
quence analysis. DNA methylation data were analyzed
and visualized using BiQ Analyzer (http://biq-analyzer.
bioinf.mpi-sb.mpg.de/).
Cell viability, colony formation assay, cell cycle and
apoptosis analysis
Twenty four hours following transfection, 1000 trans-
fected HepG2 or Huh7 cells were plated on a fresh 96-
well plate in triplicate and maintained in DMEM contain-
ing 10% FBS for 5 days to assess cellular viability. Cells
were tested for proliferation every 24 hours using Cell
Titer-Blue cell viability assay (Promega Corp.) according
to the manufacturer’s instructions and the fluorescence
values were recorded using a multi-plate reader (Synergy
2, BioTek). For colony formation assays, 2000 transfected
HepG2 or Huh7 were plated on a fresh 6-well plate in
triplicate and maintained in DMEM containing 10% FBS
for 2 weeks. Cell colonies were fixed with 20% methanol
and stained with 0.1% coomassie brilliant blue R250 at
room temperature for 15 min. The colonies were counted
using an ELIspot Bioreader 5000 (BIO-SYS, Karben, GE).
Forty eight hours following transfection, 1 × 105 trans-
fected HepG2 or Huh7 cells were harvested, washed once
in phosphate buffer saline (PBS), and fixed in 70% ethanol
at 4°C overnight. Staining for DNA content was performed
with 50 mg/mL propidium iodide and 1 mg/mL RNase A
at room temperature for 30 minutes. Populations in G0-
G1, S, and G2-M phase were measured using a Cell Lab
Quanta SC flow cytometer (Beckman Coulter, Fullerton,
CA), and the data were analyzed using FlowJo v7.6 Soft-
ware. For apoptosis analysis, cells were incubated with
FITC-Annexin V (Promega Corp.) for 15 minutes at 4°C in
the dark, according to the manufacturer’s instructions and
measured with the same system. In addition, caspase 3/7
activities of transfected HepG2 or Huh7 cells were also
measured with the Caspase-Glo 3/7 Assay (Promega Corp.)
according to manufacturer’s instructions and recorded with
a multi-plate reader (Synergy 2, BioTek).
Tumorigenicity assay in xenograft nude mice
Male BALB/c nude mice (5 to 6 weeks of age) were ob-
tained from Shanghai Experimental Animal Center
(Shanghai, China). Animal handling and experimental
procedures were approved by the Animal Experiments
Ethics Committee of Second Military Medical Univer-
sity. For the in vivo tumorigenicity assays, all pyrimidine
nucleotides in the SNORD113-1 siRNA or scramble
siRNA were substituted with their 2′-O-methyl ana-
logues to improve RNA stability. HepG2 cells (1 × 106)
transfected with p3.1-SNORD113-1 or SNORD113-1siRNA were suspended in 100 μL PBS and then injected
into the left side of the posterior flank of 6 BALB/c nude
mice each. Scramble siRNA or empty vector transfected
HepG2 cells (1 × 106) were injected subcutaneously into
the right side of same 12 mice. Tumor growth was ex-
amined daily, and the tumor volumes were calculated
every week using the formula for hemi-ellipsoids: V =
length (cm) × width (cm) × height (cm) × 0.5236. After
5 weeks, the mice were sacrificed and the tumors were
dissected and imaged.
Cell migration and invasion assays
For the cell migration assay, 2 × 105 HepG2 cells trans-
fected with p3.1-SNORD113-1 or SNORD113-1 siRNA
were seeded in the upper chamber of transwell units
(Corning, NY, USA) with 8 μm pore size polycarbonate
filters under serum-free conditions. The lower chamber
was filled with 500 μL DMEM containing 10% FBS.
After incubation for 24 h, cells on the upper surface of
the filter were completely removed by wiping with a cot-
ton swab. Then the filters were fixed with 4% parafor-
maldehyde and stained with 0.1% coomassie brilliant
blue R250 for 20 min. Cells that migrated through the
pores to the lower surface of the filter were counted and
analyzed with a digital microscope system (IX81; Olym-
pus). Triplicate samples were acquired, and the data
were expressed as the average cell number of 5 fields.
For the cell invasion assays, a protocol similar to the cell
migration assay was used, except that the transwell units
were pre-coated with 200 μg/ml Matrigel (BD Biosci-
ences, San Jose, CA, USA) and incubated overnight.
Cells that invaded through the Matrigel and reached the
lower surface of the filter were counted.
Immunoblotting
Protein extracts from HCC tissues or HepG2 cells were
prepared using a modified RIPA buffer with 0.5% sodium
dodecyl sulfate (SDS) in the presence of proteinase in-
hibitor cocktail (Complete mini, Roche, Indianapolis, IN,
USA). Fifty micrograms of protein from HCC tissues
and their adjacent non-tumor tissues were electropho-
resed in 10% SDS-PAGE mini gels and transferred onto
PVDF membranes (Immobilon P-SQ, Millipore, Billerica,
MA, USA). After blocking with 5% nonfat milk, the mem-
branes were incubated with primary antibodies at 4°C
overnight, followed by incubation with HRP-conjugated
goat anti-rabbit or goat anti-mouse antibody (1:10000 di-
lution, KPL, Gaithersburg, MA,USA) for 1 hour at room
temperature. Signals were developed with Super Signal
West Pico chemiluminescent substrate (Pierce, Rockford,
Il, USA), visualized using the Gene Gnome HR Image
Capture System (Syngene, Frederick, MD, USA), and ana-
lyzed with Gene tools (Syngene). The primary antibodies
were: MEK, p-MEK, ERK, p-ERK, SMAD2/3, p-SMAD2/3
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USA), and GAPDH (1:5000 dilution, Epitomics Inc.,
Burlingame, CA, USA).
Cancer pathway reporter assays
HepG2 cells transfected with p3.1-SNORD113-1 or
SNORD113-1 siRNA were examined using Cignal Finder
10 Cancer Pathway Reporter Assays (Qiagen Inc., Valencia,
CA, USA) according to the manufacturer’s protocol. In
brief, cells were seeded onto 96-well plates containing lucif-
erase reporters from 10 common cancer pathways along
with FuGene HD transfection reagent. Forty eight hours
later, the luciferase activities of cells were measured using
the Dual Luciferase Assay system (Promega). Relative firefly
luciferase activity was calculated and normalized to the
constitutively expressed Renilla luciferase.
Statistical analysis
All experiments were performed at least three times,
and data are presented as mean ± SD. Comparisons were
made by using a two-tailed t test or one-way ANOVA
for experiments with more than two subgroups. Correl-
ation analysis was made by using Spearman correlation
coefficient. Association of SNORD113-1 expression with
cancer specific survival rate was analyzed using the
Kaplan-Meier method.
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